Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sham Mailankody

Showing results (21-30 of 174) with videos related to

Pageof 18
Sort By:
Best Practice & Research. Clinical Haematology|March 7, 2020
CAR T and CAR NK cells in multiple myeloma: Expanding the targetsUrvi A Shah, Sham Mailankody
Seminars in Oncology|January 8, 2017
Controversies in multiple myeloma: Evidence-based updateInhye E Ahn, Sham Mailankody
Nature Medicine|June 17, 2026
CAR T cells take on precancersEric M Jurgens, Sham Mailankody
Hematology. American Society of Hematology. Education Program|December 9, 2023
Current use of CAR T cells to treat multiple myelomaRoss S Firestone, Sham Mailankody
Annals of Internal Medicine|April 4, 2018
Money-Back Guarantees for Expensive Drugs: Wolf's Clothing but a Sheep UnderneathSham Mailankody, Peter B Bach
Seminars in Oncology|May 15, 2016
ASCO Plenary Sessions: impact, legacy, futureAndrae Vandross, Vinay Prasad, Sham Mailankody
JAMA Oncology|December 30, 2017
Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid CancersVinay Prasad, Victoria Kaestner, Sham Mailankody
The New England Journal of Medicine|December 14, 2011
Myeloma and second primary cancersOla Landgren, Anish Thomas, Sham Mailankody
JAMA Otolaryngology-- Head & Neck Surgery|July 29, 2014
Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley LectureTito Fojo, Sham Mailankody, Andrew Lo
Journal of Global Oncology|July 19, 2017
Ethics of Clinical Trials in Low-Resource Settings: Lessons From Recent Trials in Cancer MedicineVinay Prasad, Hemanth Kumar, Sham Mailankody
Pageof 18

Showing results (21-30 of 174) with videos related to

Sort By:
Pageof 18
Best Practice & Research. Clinical Haematology|March 7, 2020
CAR T and CAR NK cells in multiple myeloma: Expanding the targetsUrvi A Shah, Sham Mailankody
Seminars in Oncology|January 8, 2017
Controversies in multiple myeloma: Evidence-based updateInhye E Ahn, Sham Mailankody
Nature Medicine|June 17, 2026
CAR T cells take on precancersEric M Jurgens, Sham Mailankody
Hematology. American Society of Hematology. Education Program|December 9, 2023
Current use of CAR T cells to treat multiple myelomaRoss S Firestone, Sham Mailankody
Annals of Internal Medicine|April 4, 2018
Money-Back Guarantees for Expensive Drugs: Wolf's Clothing but a Sheep UnderneathSham Mailankody, Peter B Bach
Seminars in Oncology|May 15, 2016
ASCO Plenary Sessions: impact, legacy, futureAndrae Vandross, Vinay Prasad, Sham Mailankody
JAMA Oncology|December 30, 2017
Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid CancersVinay Prasad, Victoria Kaestner, Sham Mailankody
The New England Journal of Medicine|December 14, 2011
Myeloma and second primary cancersOla Landgren, Anish Thomas, Sham Mailankody
JAMA Otolaryngology-- Head & Neck Surgery|July 29, 2014
Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley LectureTito Fojo, Sham Mailankody, Andrew Lo
Journal of Global Oncology|July 19, 2017
Ethics of Clinical Trials in Low-Resource Settings: Lessons From Recent Trials in Cancer MedicineVinay Prasad, Hemanth Kumar, Sham Mailankody
Pageof 18